A 60-year-old Ukrainian male patient,previously diagnosed with indolent lymphoma,developed aggressive large B-cell lymphoma accompanied by poor prognostic factors including TP53 mutation.In pursuit of better treatment,the patient traveled to multiple locations including Israel and Turkey,where they underwent mono-targeted CAR-T therapy,achieving temporary remission.However,the disease relapsed after nine months.While undergoing treatment at a leading private hospital in Istanbul,Turkey,the patient coincidentally encountered GoBroad Medical Team,who were there on an academic visit.During their exchange,GoBroad Medical Team's proposed treatment plan and the research accomplishments of her hospital garnered high praise from local experts.Consequently,the patient was referred to GoBroad Medical center for further treatment.

An individualized treatment plan was developed upon further pathology tests and underlying genetic analysis.The plan included bridging therapy of a CD38 mAb combined with chemotherapy to reduce tumor burden,complemented by a BTK inhibitor and low-dose radiotherapy to improve the immune microenvironment,followed by CAR-T sequential therapy targeting CD20 and CD79B.The initial treatment went smoothly.However,the patient had a positive test for COVID-19 just a few days before CAR-T cell infusion.The team decided to continue the CAR-T cell infusion as planned on the basis of comprehensive prevention and control after fully weighing the benefits and risks of the patient.Finally,the CAR-T cell infusion went smoothly.Although cytokine release syndrome occurred,the symptoms were manageable,and lesions remain stable,and no serious complications were observed.Eleven days post-infusion,the patient's COVID-19 status turned negative,and cell expansion was deemed ideal.The patient's condition is currently stable,and there is optimism that they may be able to travel to Ukraine for a reunion with family and friends in time for their 60th birthday.Moving forward,the hospital intends to maintain close contact and collaboration with the patient's local hospital,continually refining the management plan to ensure the longevity of therapeutic efficacy and the patient's quality of life.